KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short-term Investments (2016 - 2018)

Historic Short-term Investments for Travere Therapeutics (TVTX) over the last 6 years, with Q2 2018 value amounting to $166.4 million.

  • Travere Therapeutics' Short-term Investments fell 1951.23% to $166.4 million in Q2 2018 from the same period last year, while for Jun 2018 it was $166.4 million, marking a year-over-year decrease of 1951.23%. This contributed to the annual value of $201.2 million for FY2017, which is 634.57% down from last year.
  • According to the latest figures from Q2 2018, Travere Therapeutics' Short-term Investments is $166.4 million, which was down 1951.23% from $202.9 million recorded in Q1 2018.
  • Travere Therapeutics' Short-term Investments' 5-year high stood at $250.4 million during Q3 2016, with a 5-year trough of $5.9 million in Q2 2015.
  • Over the past 5 years, Travere Therapeutics' median Short-term Investments value was $199.7 million (recorded in 2016), while the average stood at $148.3 million.
  • As far as peak fluctuations go, Travere Therapeutics' Short-term Investments soared by 708528.66% in 2014, and later tumbled by 1951.23% in 2018.
  • Quarter analysis of 5 years shows Travere Therapeutics' Short-term Investments stood at $9.6 million in 2014, then skyrocketed by 1907.11% to $191.8 million in 2015, then grew by 12.03% to $214.9 million in 2016, then decreased by 6.35% to $201.2 million in 2017, then dropped by 17.32% to $166.4 million in 2018.
  • Its Short-term Investments stands at $166.4 million for Q2 2018, versus $202.9 million for Q1 2018 and $201.2 million for Q4 2017.